$37.80
0.160.42%
Last update: 1:01 PM
15 minutes delayed
Sector
Healthcare
Region
US
AUM
115.14M
Fund Score
ALPS Medical Breakthroughs ETF (ARCA:SBIO) Quotes, Forecast and News Summary
ALPS Medical Breakthroughs ETF (ARCA: SBIO) stock price, news, charts, stock research, profile.
| Open | $37.55 |
| High | $37.88 |
| 52 Wk High | 38.80 |
| AUM | 115.14M |
| Dividend | $0.07 |
| Ex-Div Date | Dec 21, 2023 |
| Volume | 2.48K |
| Market Cap | $4.11B |
| Mgmt Fee | 0.5% |
| P/E Ratio | 26.68 |
| Prev. Close | $37.64 |
| Low | $37.48 |
| 52 Wk Low | 23.21 |
| Shares Out | 3.20M |
| Yield | 0.19% |
| Div. Freq | Annual |
| Avg. Volume Daily | 8.29K |
| Beta | 0.88 |
| Avg. Expense Ratio | 0.5% |
| P/B Ratio | 3.71 |
Recent News
FAQ
How do I buy ALPS Medical Breakthroughs ETF (SBIO) stock?
You can purchase shares of ALPS Medical Breakthroughs ETF (ARCA:SBIO) through any online brokerage.
Who are ALPS Medical Breakthroughs ETF (SBIO) competitors?
There are no as such competitors for ALPS Medical Breakthroughs ETF.
What is the target price for ALPS Medical Breakthroughs ETF (SBIO) stock?
There is no analysis for ALPS Medical Breakthroughs ETF.
What is the forecast for ALPS Medical Breakthroughs ETF (SBIO) stock?
There is no analysis for ALPS Medical Breakthroughs ETF to provide a consensus price target.
Current stock price for ALPS Medical Breakthroughs ETF (SBIO)?
The stock price for ALPS Medical Breakthroughs ETF (ARCA: SBIO) is $37.8019 last updated Today at July 24, 2024 at 1:01 PM EDT.
Does ALPS Medical Breakthroughs ETF (SBIO) pay a dividend?
A quarterly cash dividend of 0.58 per share of Class A Common Stock. The quarterly cash dividend was payable on December 28, 2017 to stockholders of record on December 21, 2017.
When is ALPS Medical Breakthroughs ETF (ARCA:SBIO) reporting earnings?
ALPS Medical Breakthroughs ETF does not have any upcoming earnings scheduled.
Is ALPS Medical Breakthroughs ETF (SBIO) going to split?
There is no upcoming split for ALPS Medical Breakthroughs ETF.
ETF Details
| Sector | Healthcare |
| Category | Mid Performer-Mid Growth |
| Investment Style | Small Cap Growth |
| Fund Inception | Dec 30, 2014 |
| Managers | Charles Perkins Ryan Mischke Andrew Hicks |
| Definition | Most of the stocks in this Equity Fund have average financial performance and average growth potential |
Investment Policy
The fund employs a passive management - or indexing - investment approach designed to track the performance of the underlying index. It will normally invest at least 80% of its net assets in securities that comprise the underlying index. The underlying index is comprised of small- and mid-cap stocks of biotechnology companies that have one or more drugs in either Phase II or Phase III of the U.S. Food and Drug Administration clinical trials.
Top ETF Holdings
| Symbol | Name | Share % |
|---|---|---|
| PCVX | Vaxcyte Inc | 5.18% |
| CERE | Cerevel Therapeutics H... | 5.04% |
| VKTX | Viking Therapeutics In... | 4.45% |
| RVMD | Revolution Medicines I... | 4.30% |
| SMMT | Summit Therapeutics Pl... | 4.14% |
| IE | Alkermes Plc | 2.67% |
| AXSM | Axsome Therapeutics, I... | 2.37% |
| CRNX | Crinetics Pharmaceutic... | 2.36% |
| CORT | Corcept Therapeutics I... | 2.13% |
| MRUS | Merus Nv | 2.10% |